p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells

Although PS-341 (bortezomib) is a promising agent to improve multiple myeloma (MM) patient outcome, 65% of patients with relapsed and refractory disease do not respond. We have previously shown that heat shock protein (Hsp)27 is upregulated after PS-341 treatment, that overexpression of Hsp27 confers PS-341 resistance, and that inhibition of Hsp27 overcomes PS-341 resistance. Since Hsp27 is a downstream target of p38 mitogen-activated protein kinase (MAPK)/MAPK-mitogen-activated protein kinase-2 (MAPKAPK2), we hypothesized that inhibition of p38 MAPK activity could augment PS-341 cytotoxicity by downregulating Hsp27. Although p38 MAPK inhibitor SCIO-469 (Scios Inc, CA, USA) alone did not induce significant growth inhibition, it blocked baseline and PS-341-triggered phosphorylation of p38 MAPK as well as upregulation of Hsp27, associated with enhanced cytotoxicity in MM.1S cells. Importantly, SCIO-469 enhanced phosphorylation of c-Jun NH2-terminal kinase (JNK) and augmented cleavage of caspase-8 and poly(ADP)-ribose polymerase. Moreover, SCIO-469 downregulated PS-341-induced increases in G2/M-phase cells, associated with downregulation of p21Cip1 expression. Importantly, SCIO-469 treatment augmented cytotoxicity of PS-341 even against PS-341-resistant cell lines and patient MM cells. These studies therefore provide the framework for clinical trials of SCIO-469 to enhance sensitivity and overcome resistance to PS-341, thereby improving patient outcome in MM.

[1]  P. Richardson,et al.  The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: therapeutic applications , 2001, Oncogene.

[2]  D. Chauhan,et al.  Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma , 2001, Oncogene.

[3]  I. Gojo,et al.  Myeloid cell factor-1 is a critical survival factor for multiple myeloma. , 2002, Blood.

[4]  G. Haegeman,et al.  p38 and Extracellular Signal-regulated Kinase Mitogen-activated Protein Kinase Pathways Are Required for Nuclear Factor-κB p65 Transactivation Mediated by Tumor Necrosis Factor* , 1998, The Journal of Biological Chemistry.

[5]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[6]  P. Richardson,et al.  Biologic sequelae of c-Jun NH2-terminal kinase (JNK) activation in multiple myeloma cell lines , 2003, Oncogene.

[7]  S. Watson,et al.  Platelet-collagen interaction: is GPVI the central receptor? , 2003, Blood.

[8]  K. Anderson,et al.  The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. , 2003, Blood.

[9]  Yoichi Taya,et al.  DNA Damage-Induced Phosphorylation of p53 Alleviates Inhibition by MDM2 , 1997, Cell.

[10]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[11]  J. D. Vos,et al.  A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells , 2003, Oncogene.

[12]  N. Munshi,et al.  JNK-dependent Release of Mitochondrial Protein, Smac, during Apoptosis in Multiple Myeloma (MM) Cells* , 2003, The Journal of Biological Chemistry.

[13]  D. Thuerauf,et al.  p38 MAPK and NF-kappa B collaborate to induce interleukin-6 gene expression and release. Evidence for a cytoprotective autocrine signaling pathway in a cardiac myocyte model system. , 2000, The Journal of biological chemistry.

[14]  R. Morimoto,et al.  Role of the heat shock response and molecular chaperones in oncogenesis and cell death. , 2000, Journal of the National Cancer Institute.

[15]  K. Anderson,et al.  Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. , 2003, Blood.

[16]  T. McDonnell,et al.  Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53 , 1998, Oncogene.

[17]  N. Munshi,et al.  Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma , 2003, Oncogene.

[18]  T. Hideshima,et al.  Molecular mechanisms of novel therapeutic approaches for multiple myeloma , 2002, Nature Reviews Cancer.

[19]  Bart Barlogie,et al.  A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[20]  T. Libermann,et al.  Molecular sequelae of proteasome inhibition in human multiple myeloma cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[21]  T. Cotter,et al.  Heat shock proteins – modulators of apoptosis in tumour cells , 2000, Leukemia.

[22]  N. Munshi,et al.  Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. , 2003, Blood.

[23]  M. Sporn,et al.  The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. , 2004, Blood.

[24]  Masaharu Akiyama,et al.  Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. , 2003, Blood.

[25]  T. Libermann,et al.  Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. , 1996, Blood.

[26]  U. Christians,et al.  Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus , 2002, Clinical pharmacokinetics.

[27]  U. Lopes,et al.  p53-dependent Induction of Apoptosis by Proteasome Inhibitors* , 1997, The Journal of Biological Chemistry.